WO2000050089A3 - Regulation of the stability of recombinant proteins and antiboodies - Google Patents

Regulation of the stability of recombinant proteins and antiboodies Download PDF

Info

Publication number
WO2000050089A3
WO2000050089A3 PCT/US2000/004749 US0004749W WO0050089A3 WO 2000050089 A3 WO2000050089 A3 WO 2000050089A3 US 0004749 W US0004749 W US 0004749W WO 0050089 A3 WO0050089 A3 WO 0050089A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
antibody
antiboodies
regulation
stability
Prior art date
Application number
PCT/US2000/004749
Other languages
French (fr)
Other versions
WO2000050089A2 (en
Inventor
Daniel G Chain
Original Assignee
Daniel G Chain
Mindset Biopharmaceuticals Usa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12210399P priority Critical
Priority to US60/122,103 priority
Application filed by Daniel G Chain, Mindset Biopharmaceuticals Usa filed Critical Daniel G Chain
Publication of WO2000050089A2 publication Critical patent/WO2000050089A2/en
Publication of WO2000050089A3 publication Critical patent/WO2000050089A3/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies

Abstract

An antibody to a drug of interest is caused to be expressed in a target cell of interest by genetic therapy. This antibody is expressed along with a promoter and modulator for the antibody. The drug is administered to the patient, where it binds to the antibody for the drug until a critical concentration of drug is reached at the target site. Once this critical concentration of drug is achieved, the antibody is released from the drug/antibody conjugate, and the drug is available at the target site in concentrations sufficient to treat the condition for which the drug is administered. In order to ensure that the antibodies are degraded at the proper time, the antibodies are designed to have built-in signals for degradation.
PCT/US2000/004749 1999-02-26 2000-02-25 Regulation of the stability of recombinant proteins and antiboodies WO2000050089A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12210399P true 1999-02-26 1999-02-26
US60/122,103 1999-02-26

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU36048/00A AU3604800A (en) 1999-02-26 2000-02-25 Method for regulating the stability of recombinant proteins, and antibodies and products useful therein

Publications (2)

Publication Number Publication Date
WO2000050089A2 WO2000050089A2 (en) 2000-08-31
WO2000050089A3 true WO2000050089A3 (en) 2001-03-29

Family

ID=22400626

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/004749 WO2000050089A2 (en) 1999-02-26 2000-02-25 Regulation of the stability of recombinant proteins and antiboodies

Country Status (2)

Country Link
AU (1) AU3604800A (en)
WO (1) WO2000050089A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1514114A4 (en) * 2002-06-05 2007-03-21 Sopherion Therapeutics Inc Method to screen ligands using eukaryotic cell display
CA2637707A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000356A1 (en) * 1989-06-30 1991-01-10 Massachusetts Institute Of Technology Inhibition of the n-end rule pathway in living cells
FR2706486A1 (en) * 1993-06-16 1994-12-23 Rhone Poulenc Rorer Sa nucleic acid sequences, vectors containing the same, pharmaceutical compositions and therapeutic uses.
WO1996026733A1 (en) * 1995-03-01 1996-09-06 Alexander Varshavsky Codominance-mediated toxins
US5705387A (en) * 1994-02-04 1998-01-06 California Institute Of Technology Heat-inducible N-degron module
WO1998003538A2 (en) * 1995-10-27 1998-01-29 California Institute Of Technology Signal-regulated, cleavage-mediated toxins
US5763212A (en) * 1994-02-04 1998-06-09 California Institute Of Technology Inhibiting degradation of a degron-bearing protein
US5851829A (en) * 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
WO1999014353A2 (en) * 1997-09-19 1999-03-25 Dana-Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
WO2000042185A1 (en) * 1999-01-11 2000-07-20 Mindset Biopharmaceuticals (Usa), Inc. Methods for regulating the stability of recombinant proteins and products useful therein

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000356A1 (en) * 1989-06-30 1991-01-10 Massachusetts Institute Of Technology Inhibition of the n-end rule pathway in living cells
FR2706486A1 (en) * 1993-06-16 1994-12-23 Rhone Poulenc Rorer Sa nucleic acid sequences, vectors containing the same, pharmaceutical compositions and therapeutic uses.
US5851829A (en) * 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
US5705387A (en) * 1994-02-04 1998-01-06 California Institute Of Technology Heat-inducible N-degron module
US5763212A (en) * 1994-02-04 1998-06-09 California Institute Of Technology Inhibiting degradation of a degron-bearing protein
WO1996026733A1 (en) * 1995-03-01 1996-09-06 Alexander Varshavsky Codominance-mediated toxins
WO1998003538A2 (en) * 1995-10-27 1998-01-29 California Institute Of Technology Signal-regulated, cleavage-mediated toxins
WO1999014353A2 (en) * 1997-09-19 1999-03-25 Dana-Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
WO2000042185A1 (en) * 1999-01-11 2000-07-20 Mindset Biopharmaceuticals (Usa), Inc. Methods for regulating the stability of recombinant proteins and products useful therein

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A VARSHAVSKY: "The N-end rule: Functions, mysteries, uses", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 93, October 1996 (1996-10-01), pages 12142 - 12149, XP002138160, ISSN: 0027-8424 *
BALTHASAR J P ET AL: "INVERSE TARGETING OF PERITONEAL TUMORS: SELECTIVE ALTERATION OF THEANTIBODIES AND ANTIBODY FRAGMENTS. DISPOSITION OF METHOTREXATE THROUGH THE USE OF ANTI-METHOTREXATE", JOURNAL OF PHARMACEUTICAL SCIENCES,US,AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, vol. 85, no. 10, 1 October 1996 (1996-10-01), pages 1035 - 1043, XP000626797, ISSN: 0022-3549 *
DOHMEN R JURGEN ET AL: "Heat-inducible degron: A method for constructing temperature-sensitive mutants", SCIENCE,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,US, vol. 263, no. 5151, 1994, pages 1273 - 1276, XP002142706, ISSN: 0036-8075 *
LEVY, FREDERIC ET AL: "Analysis of a conditional degradation signal in yeast and mammalian cells", EUR. J. BIOCHEM., VOL. 259, NO. 1/2, PAGE(S) 244-252, January 1999 (1999-01-01), XP000971525 *
NAVARRO-TEULON I ET AL: "Expression in Escherichia coli of soluble and M13 phage-displayed forms of a single-chain antibody fragment specific for digoxin: assessment in a novel drug immunoassay", IMMUNOTECHNOLOGY,NL,ELSEVIER SCIENCE PUBLISHERS BV, vol. 1, no. 1, 1 May 1995 (1995-05-01), pages 41 - 52, XP004052683, ISSN: 1380-2933 *
ROBERTS C J ET AL: "Development of an ELISA using a universal method of enzyme-labelling drug-specific antibodies - Part I: Detection of dexamethasone in equine urine", JOURNAL OF IMMUNOLOGICAL METHODS,NL,ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, vol. 181, no. 2, 26 April 1995 (1995-04-26), pages 157 - 166, XP004021203, ISSN: 0022-1759 *
VARSHAVSKY A ET AL: "THE N-END RULE OF SELECTIVE PROTEIN TURNOVER - MECHANISTIC ASPECTS AND FUNCTIONAL IMPLICATIONS", 1988, M. RECHSTEINER (ED.): "UBIQUITIN", PLENUM PRESS CO., LONDON, GB, PAGE(S) 287-324,, ISBN: 0-306-42850-4, XP000971521 *
VARSHAVSKY A: "CODOMINANCE AND TOXINS: A PATH TO DRUGS OF NEARLY UNLIMITED SELECTIVITY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 92, April 1995 (1995-04-01), pages 3663 - 3667, XP000929682, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2000050089A2 (en) 2000-08-31
AU3604800A (en) 2000-09-14

Similar Documents

Publication Publication Date Title
Dube et al. Food intake elicited by central administration of orexins/hypocretins: identification of hypothalamic sites of action
Egleton et al. Development of neuropeptide drugs that cross the blood-brain barrier
ES2397302T3 (en) Antisense oligonucleotide against the R isoform of human acetylcholinesterase (ACHE-R) and its uses
EP0400472B1 (en) Process for preparing polyethylene glycol derivatives and modified protein.
Talman et al. Evidence for L-glutamate as the neurotransmitter of baroreceptor afferent nerve fibers
Wallace et al. Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine
JP2547054B2 (en) Chimeric peptides and compositions containing the same
Kogai et al. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics
Ziedén et al. Increased plasma 7β-hydroxycholesterol concentrations in a population with a high risk for cardiovascular disease
Świergosz‐Kowalewska Cadmium distribution and toxicity in tissues of small rodents
Rautio et al. Prodrug approaches for CNS delivery
Rosskamp et al. Long-acting insulin analogs
Liang et al. The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat
US8735350B2 (en) Reversible pegylated drugs
Breeuwer et al. Facilitated nuclear transport of histone H1 and other small nucleophilic proteins
Ziv et al. Intestinal absorption of peptides through the enterocytes
Johnson et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure
US5786340A (en) Gene transfer to the intestine
Weinmann et al. Intrathecally infused antibodies against Nogo-A penetrate the CNS and downregulate the endogenous neurite growth inhibitor Nogo-A
Leof et al. Epidermal growth factor (EGF) is required only during the traverse of early G1 in PDGF stimulated density-arrested BALB/c-3T3 cells
Maiese et al. Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies
Ahlskog et al. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives
ES2726945T3 (en) Conjugation Methods
Zoja et al. Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators
Drüeke et al. Progress in uremic toxin research: beta2‐microglobulin

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase